Response to: 'Concerns about the operational definition of remission in 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus' by Rua-Figueroa and Erausquin
Ann Rheum Dis
.
2020 Oct;79(10):e132.
doi: 10.1136/annrheumdis-2019-215810.
Epub 2019 Jul 3.
Authors
Antonis Fanouriakis
1
,
George Bertsias
2
3
,
Dimitrios T Boumpas
4
5
6
Affiliations
1
Rheumatology and Clinical Immunology, 4th Department of Internal Medicine, "Attikon" University Hospital, Athens, Greece.
2
Department of Rheumatology, Clinical Immunology and Allergy, University Hospital of Heraklion, Heraklion, Greece.
3
Laboratory of Autoimmunity-Inflammation, Institute of Molecular Biology and Biotechnology, Heraklion, Greece.
4
Rheumatology and Clinical Immunology, 4th Department of Internal Medicine, "Attikon" University Hospital, Athens, Greece boumpasd@uoc.gr.
5
Laboratory of Autoimmunity and Inflammation, Biomedical Research Foundation of the Academy of Athens, Athens, Greece.
6
Joint Academic Rheumatology Program, Medical School, National and Kapodestrian University of Athens, Athens, Greece.
PMID:
31270111
DOI:
10.1136/annrheumdis-2019-215810
No abstract available
Keywords:
disease activity; systemic lupus erythematosus; treatment.
Publication types
Comment
MeSH terms
Humans
Lupus Erythematosus, Systemic* / drug therapy
Research Design